PMID- 28145647
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20220316
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 32
IP  - 3
DP  - 2017 Mar
TI  - Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of 
      Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different 
      Disease Severity.
PG  - 439-447
LID - 10.3346/jkms.2017.32.3.439 [doi]
AB  - This study explored the relationship between the fractional exhaled nitric oxide 
      (FeNO) level and the efficacy of inhaled corticosteroid (ICS) in asthma-chronic 
      obstructive pulmonary disease (COPD) overlap syndrome (ACOS) patients with 
      different disease severity. A total of 127 ACOS patients with ACOS (case group) 
      and 131 healthy people (control group) were enrolled in this study. Based on the 
      severity of COPD, the ACOS patients were divided into: mild ACOS; moderate ACOS; 
      severe ACOS; and extremely severe ACOS groups. We compared FeNO levels, pulmonary 
      function parameters including percentage of forced expiratory volume in 1 second 
      (FEV1) to predicted value (FEV1%pred), ratio of FEV1 to forced vital capacity 
      (FEV1/FVC), inspiratory capacity to total lung capacity (IC/TLC) and residual 
      volume to total lung capacity (RV/TLC), arterial blood gas parameters, including 
      PH, arterial partial pressure of oxygen (PaO(2)) and arterial partial pressure of 
      carbon dioxide (PaCO(2)), total serum immunoglobulin E (IgE), induced sputum 
      eosinophil (EOS), plasma surfactant protein A (SP-A), plasma soluble receptor for 
      advanced glycation end products (sRAGE), sputum myeloperoxidase (MPO), sputum 
      neutrophil gelatinase-associated lipocalin (NGAL) and Asthma Control Test (ACT) 
      scores, and COPD Assessment Test (CAT) scores. Compared with pre-treatment 
      parameters, the FeNO levels, RV/TLC, PaCO(2), total serum IgE, induced sputum EOS, 
      plasma SP-A, sputum MPO, sputum NGAL, and CAT scores were significantly decreased 
      after 6 months of ICS treatment, while FEV1%pred, FEV1/FVC, IC/TLC, PH, PaO2, 
      plasma sRAGE, and ACT scores were significantly increased in ACOS patients with 
      different disease severity after 6 months of ICS treatment. This finding suggests 
      that the FeNO level may accurately predict the efficacy of ICS in the treatment 
      of ACOS patients.
FAU - Feng, Jia Xi
AU  - Feng JX
AUID- ORCID: 0000-0003-4814-8648
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - Lin, Yun
AU  - Lin Y
AUID- ORCID: 0000-0002-2576-3827
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - Lin, Jian
AU  - Lin J
AUID- ORCID: 0000-0003-2510-9064
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - He, Su Su
AU  - He SS
AUID- ORCID: 0000-0003-0035-0003
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - Chen, Mei Fang
AU  - Chen MF
AUID- ORCID: 0000-0003-0070-0931
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - Wu, Xiao Mai
AU  - Wu XM
AUID- ORCID: 0000-0002-3115-3988
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China.
FAU - Xu, You Zu
AU  - Xu YZ
AUID- ORCID: 0000-0002-1252-9564
AD  - Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, 
      Linhai, China. Youzuxu@163.com.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Biomarkers)
RN  - 0 (Lipocalin-2)
RN  - 0 (Pulmonary Surfactant-Associated Protein A)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Asthma/complications/*drug therapy/pathology
MH  - Biomarkers/blood/metabolism
MH  - Blood Gas Analysis
MH  - Case-Control Studies
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Lipocalin-2/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/*analysis
MH  - Peroxidase/metabolism
MH  - Pulmonary Disease, Chronic Obstructive/complications/*drug therapy/pathology
MH  - Pulmonary Surfactant-Associated Protein A/blood
MH  - Receptor for Advanced Glycation End Products/blood
MH  - Respiratory Function Tests
MH  - Severity of Illness Index
MH  - Sputum/enzymology/metabolism
PMC - PMC5290103
OTO - NOTNLM
OT  - Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
OT  - Efficacy
OT  - Fractional Exhaled Nitric Oxide
OT  - Inhaled Corticosteroid
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2017/02/02 06:00
MHDA- 2017/04/01 06:00
PMCR- 2017/03/01
CRDT- 2017/02/02 06:00
PHST- 2016/04/22 00:00 [received]
PHST- 2016/10/30 00:00 [accepted]
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2017/02/02 06:00 [entrez]
PHST- 2017/02/02 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
AID - 32.439 [pii]
AID - 10.3346/jkms.2017.32.3.439 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2017 Mar;32(3):439-447. doi: 10.3346/jkms.2017.32.3.439.